Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07274644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 22, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary endpoint(s) modified Secondary endpoints: 11 to 16v3 Show 1 more changeShow less
    • Secondary endpoints: 11 to 16

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Enrolling by Invitation to Active, Not Recruiting Primary completion date: May 30, 2026 to Jun 30, 2026 · Completion date: Jun 30, 2026 to Jul 30, 2026v2 Show 2 more changesShow less
    • Primary completion date: May 30, 2026 to Jun 30, 2026
    • Completion date: Jun 30, 2026 to Jul 30, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, randomized, open-label, controlled clinical trial to compare the effects of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) versus insulin glargine 100 U/mL (iGlar) on liver fat content in patients with Type 2 Diabetes (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The study includes a 12-week treatment period.
Trial Details
NCT Number NCT07274644
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease, Diabetes Mellitus Type 2
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov